Language: BG BG
← Back to results
Active (not recruiting) Phase 2 NCT07028749

Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol

Phase 2 – studying effectiveness and dosage
Conditions: Hypertriglyceridemia

Sponsor: Marea Therapeutics

trial.available_in: БГ
Overview
The primary objective of the study is to evaluate the effect of MAR001 compared to placebo on levels of the TG and RC in adults with elevated TG and RC.
Who can participate
Inclusion Criteria: * Elevated fasting TGs and RC * Elevated nonfasting TGs and RC * Fasting LDL-C ≥ 50 mg/dL (≥ 1.29 mmol/L) and ≤ 130 mg/dL (≤ 3.36 mmol/L) * Willingness to provide informed consent and comply with the intervention and all study assessments * Stable diet for a minimum of 3 months prior to screening and with no plans to change diet through duration of study * Stable drug regimen (if relevant) prior to screening visit and no planned changes during screening or trial participation Exclusion Criteria: * Acute or chronic liver disease * TG concentration ≥880mg/dl * History of type 1 diabetes mellitus or history of diabetic ketoacidosis * Newly diagnosed T2DM * Participants with known active hepatitis A, B, or C * Uncontrolled hypothyroidism * Any condition that prevents the participant from complying with study procedures
Locations 4
Australia (1)
Marea Site 103
Canberra , Australian Capital Territory
Canada (1)
Marea Site 406
Concord , Ontario
New Zealand (1)
Marea Site 211
Birkenhead , Auckland
United States (1)
Marea Site 328
Anniston , Alabama
Technical details
Status
Active (not recruiting)
Phase
Phase 2
Study type
INTERVENTIONAL
Sex
Male and female
Minimum age
18 Years
Maximum age
75 Years
Healthy volunteers
No
Start date
30.06.2025
Completion date
01.12.2026
Registry ID
NCT07028749
Source
anzctr
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.